Logo image of ALVO

ALVOTECH SA (ALVO) Stock Fundamental Analysis

NASDAQ:ALVO - Nasdaq - LU2458332611 - Common Stock - Currency: USD

12.28  +0.58 (+4.96%)

After market: 12.48 +0.2 (+1.63%)

Fundamental Rating

3

ALVO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. ALVO may be in some trouble as it scores bad on both profitability and health. ALVO is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALVO has reported negative net income.
In the past year ALVO has reported a negative cash flow from operations.
In the past 5 years ALVO always reported negative net income.
ALVO had a negative operating cash flow in each of the past 5 years.
ALVO Yearly Net Income VS EBIT VS OCF VS FCFALVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -100M -200M -300M -400M -500M

1.2 Ratios

The Return On Assets of ALVO (-35.80%) is better than 61.46% of its industry peers.
Industry RankSector Rank
ROA -35.8%
ROE N/A
ROIC N/A
ROA(3y)-45.68%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVO Yearly ROA, ROE, ROICALVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 50 -50

1.3 Margins

Looking at the Gross Margin, with a value of 59.03%, ALVO is in the better half of the industry, outperforming 78.86% of the companies in the same industry.
ALVO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVO Yearly Profit, Operating, Gross MarginsALVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

ALVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALVO has been increased compared to 1 year ago.
ALVO has a worse debt/assets ratio than last year.
ALVO Yearly Shares OutstandingALVO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 50M 100M 150M 200M 250M
ALVO Yearly Total Debt VS Total AssetsALVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.74, we must say that ALVO is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of -0.74, ALVO is doing good in the industry, outperforming 60.04% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.74
ROIC/WACCN/A
WACC7.37%
ALVO Yearly LT Debt VS Equity VS FCFALVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 500M -500M 1B

2.3 Liquidity

ALVO has a Current Ratio of 2.69. This indicates that ALVO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.69, ALVO is doing worse than 69.80% of the companies in the same industry.
A Quick Ratio of 1.92 indicates that ALVO should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.92, ALVO is not doing good in the industry: 76.02% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 1.92
ALVO Yearly Current Assets VS Current LiabilitesALVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

7

3. Growth

3.1 Past

ALVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.74%, which is quite impressive.
ALVO shows a strong growth in Revenue. In the last year, the Revenue has grown by 517.92%.
The Revenue has been growing by 10.37% on average over the past years. This is quite good.
EPS 1Y (TTM)29.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.56%
Revenue 1Y (TTM)517.92%
Revenue growth 3Y10.37%
Revenue growth 5YN/A
Sales Q2Q%478.6%

3.2 Future

Based on estimates for the next years, ALVO will show a very strong growth in Earnings Per Share. The EPS will grow by 28.19% on average per year.
ALVO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 84.42% yearly.
EPS Next Y70.41%
EPS Next 2Y49.02%
EPS Next 3Y38.49%
EPS Next 5Y28.19%
Revenue Next Year306.52%
Revenue Next 2Y139.79%
Revenue Next 3Y94.2%
Revenue Next 5Y84.42%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALVO Yearly Revenue VS EstimatesALVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 500M 1B 1.5B
ALVO Yearly EPS VS EstimatesALVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ALVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 48.55, ALVO can be considered very expensive at the moment.
ALVO's Price/Forward Earnings ratio is rather cheap when compared to the industry. ALVO is cheaper than 91.83% of the companies in the same industry.
ALVO is valuated expensively when we compare the Price/Forward Earnings ratio to 22.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 48.55
ALVO Price Earnings VS Forward Price EarningsALVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

ALVO's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALVO is cheaper than 92.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 535.81
ALVO Per share dataALVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALVO's earnings are expected to grow with 38.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.02%
EPS Next 3Y38.49%

More info and screens

0

5. Dividend

5.1 Amount

ALVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALVOTECH SA

NASDAQ:ALVO (2/21/2025, 8:00:57 PM)

After market: 12.48 +0.2 (+1.63%)

12.28

+0.58 (+4.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners5.83%
Inst Owner ChangeN/A
Ins Owners0.61%
Ins Owner ChangeN/A
Market Cap3.70B
Analysts82
Price Target19.38 (57.82%)
Short Float %0.38%
Short Ratio2.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4557.66%
Min EPS beat(2)64.99%
Max EPS beat(2)9050.33%
EPS beat(4)2
Avg EPS beat(4)1258.61%
Min EPS beat(4)-3090.2%
Max EPS beat(4)9050.33%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)5.68%
Min Revenue beat(2)-2.08%
Max Revenue beat(2)13.45%
Revenue beat(4)1
Avg Revenue beat(4)-7.14%
Min Revenue beat(4)-20.3%
Max Revenue beat(4)13.45%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.17%
PT rev (3m)-6.17%
EPS NQ rev (1m)50%
EPS NQ rev (3m)50%
EPS NY rev (1m)33.5%
EPS NY rev (3m)35.23%
Revenue NQ rev (1m)10.43%
Revenue NQ rev (3m)10.43%
Revenue NY rev (1m)0.26%
Revenue NY rev (3m)3.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 48.55
P/S 9.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 535.81
EPS(TTM)-1.85
EYN/A
EPS(NY)0.25
Fwd EY2.06%
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS1.31
BVpS-1.14
TBVpS-1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.03%
FCFM N/A
ROA(3y)-45.68%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 128.96
Cap/Depr 121.89%
Cap/Sales 9.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.69
Quick Ratio 1.92
Altman-Z -0.74
F-Score6
WACC7.37%
ROIC/WACCN/A
Cap/Depr(3y)218.46%
Cap/Depr(5y)156.69%
Cap/Sales(3y)69.93%
Cap/Sales(5y)47.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.56%
EPS Next Y70.41%
EPS Next 2Y49.02%
EPS Next 3Y38.49%
EPS Next 5Y28.19%
Revenue 1Y (TTM)517.92%
Revenue growth 3Y10.37%
Revenue growth 5YN/A
Sales Q2Q%478.6%
Revenue Next Year306.52%
Revenue Next 2Y139.79%
Revenue Next 3Y94.2%
Revenue Next 5Y84.42%
EBIT growth 1Y94.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.12%
EBIT Next 3Y55.09%
EBIT Next 5Y50.6%
FCF growth 1Y0.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.07%
OCF growth 3YN/A
OCF growth 5YN/A